Table 2 Patient characteristics (n = 34). (Location: After the sub-heading “Short-term outcomes of PV stent placement” in the Results)
Number (%) | |
|---|---|
Sex (Male: Female) | 15 (44.1%): 19 (55.9%) |
Agea | 67.0 ± 8.8 |
Underlying disease | |
Pancreatic cancer | 20 (58.8%) |
Perihilar cholangiocarcinoma | 7 (20.6%) |
Decompensated liver cirrhosis | 2 (5.9%) |
Ampullary cancer | 2 (5.9%) |
Pancreatic cancer and Perihilar cholangiocarcinoma | 1 (2.9%) |
Hepatocellular carcinoma | 1 (2.9%) |
Gallbladder cancer | 1 (2.9%) |
Surgical procedures | |
Subtotal stomach-preserving pancreatoduodenectomy | 13 (38.2%) |
Pancreatoduodenectomy | 5 (14.7%) |
Right lobectomy | 3 (8.9%) |
No surgery for pancreatic cancer | 3 (8.9%) |
Left trisectionectomy | 3 (8.9%) |
Liver transplantation | 2 (5.9%) |
Left lobectomy | 2 (5.9%) |
Hepatopancreatoduodenectomy | 1 (2.9%) |
Extended cholecystectomy | 1 (2.9%) |
Distal pancreatectomy | 1 (2.9%) |
Symptoms | |
Ascites | 9 (26.5%) |
Liver dysfunction | 5 (14.7%) |
Gastrointestinal bleeding | 5 (14.7%) |
Asymptomatic (for introducing chemotherapy or preventing portal hypertension-related symptoms) | 5 (14.7%) |
Gastrointestinal bleeding, ascites | 2 (5.9%) |
Encephalopathy | 2 (5.9%) |
Ascites, diarrhea | 2 (5.9%) |
Liver dysfunction, ascites | 1 (2.9%) |
Encephalopathy, ascites | 1 (2.9%) |
Diarrhea | 1 (2.9%) |
Intraperitoneal bleeding | 1 (2.9%) |
Range of PV stenosis or occlusion | |
PV to SMV | 16 (47.1%) |
PV | 12 (35.3%) |
SMV | 5 (14.7%) |
PV resection | 14 (41.2%) |
Neoadjuvant radiotherapy | 13 (38.2%) |
Etiology of PV stenosis (benign vs malignant) | 20 (58.8%): 14 (41.2%) |
Degree of stenosis (stenosis vs occlusion) | 16 (47.1%): 18 (52.9%) |
Lesion length (mm)a | 41.5 ± 16.0 |
Stent diameter (mm)a | 8.8 ± 1.5 |
Interval days between surgery and stent placementb | 101 (32–448) |
Approach (transhepatic vs trans-ileocecal vein) | 18 (52.9%): 16 (47.1%) |
Collateral vein (hepatofugal, hepatopetal) | 5 (14.7%): 7 (20.6%) |
Residual stenosis ≥ 30% after stent placement (in-stent, outside-stent) | 3 (8.9%): 1 (2.9%) |
Post-procedural anticoagulants | |
Warfarin | 16 (47.1%) |
Edoxaban (Lixiana®) | 10 (29.4%) |
None | 6 (17.6%) |
Apixaban (Eliquis®) | 2 (5.9%) |
Stent occlusions | 6 (17.6%) |